Epstein-Barr virus (EBV) is an important tumor-associated virus. In 1997, the World Health Organization (WHO) officially classified EBV as a Group 1 carcinogen, as it is implicated in the pathogenesis of various epithelial malignancies and multiple types of lymphomas. Epithelial malignancies associated with EBV infection include nasopharyngeal carcinoma (NPC), gastric cancer, colorectal cancer, breast cancer, cervical cancer, prostate cancer, and oral cancer, among others. Currently, optimal therapeutic strategies for EBV-associated tumors remain lacking, particularly in patients with recurrent, metastatic, or refractory disease. Furthermore, although EBV infection plays a significant role in the development and progression of EBV-positive tumors and may influence patient prognosis, there are currently no precision therapeutic approaches specifically targeting EBV-positive lymphomas. Thus, treatment options for this patient population warrant further attention.
EBV mRNA vaccine is a therapeutic vaccine based on messenger RNA (mRNA) targeting antigens related to EBV. This clinical trial aims to evaluate the safety, tolerability, immunogenicity, and preliminary antitumor activity of EBV mRNA vaccine in patients with advanced EBV-positive malignant tumors, thereby providing a scientific basis for subsequent clinical development.
Male or female patients aged ≥18 years;
Patients with advanced Epstein-Barr virus (EBV)-positive tumors (e.g., nasopharyngeal carcinoma, NK/T-cell lymphoma, or gastric cancer) who have failed at least two lines of standard therapy;
Eastern Cooperative Oncology Group (ECOG) performance status score: 0-2;
Estimated survival ≥3 months;
Participation in another clinical drug trial within the past 4 weeks;
History of other malignancies, unless it is cervical carcinoma in situ, treated cutaneous squamous cell carcinoma or urothelial tumors, or other malignancies that have undergone curative treatment (at least 5 years prior to enrollment);
Uncontrolled cardiac symptoms or diseases;
Female subjects who are pregnant or breastfeeding;
Sequential
EBV mRNA vaccine
Biological/VaccineEBV mRNA vaccine
Immune Checkpoint Inhibitors, ICIs
Biological/VaccineImmune Checkpoint Inhibitors, ICIs
Dose limiting toxicity (DLT)
Safety: Type, frequency, and severity of treatment-related adverse events
Objective response rate (ORR)
Disease control rate (DCR)
Progression-free survival (PFS)
Survival rate (1-year, 2-year)
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
